Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 8, 2014, Pages 1368-1374

  Armuzzi, Alessandro ^a   Pugliese, Daniela ^a   Danese, Silvio ^b   Rizzo, Gianluca ^a   Felice, Carla ^a   Marzo, Manuela ^a   Andrisani, Gianluca ^a   Fiorino, Gionata ^b   Nardone, Olga Maria ^a   De Vitis, Italo ^a   Papa, Alfredo ^a   Rapaccini, Gian Lodovico ^a   Guidi, Luisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Corticosteroid dependency; Infliximab; Observational study; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; STEROID; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COLON RESECTION; DERMATITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTIOUS COMPLICATION; INFUSION RELATED REACTION; INTESTINAL DYSMOTILITY; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SUBSCORE; OBSERVATIONAL STUDY; POST TREATMENT SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN MANIFESTATION; STEROID DEPENDENT ULCERATIVE COLITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG COMBINATION; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEROIDS; SURVIVAL RATE;

EID: 84905482221     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000115     Document Type: Article

References (23)

1. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; CD005112.
2. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
3. Reinisch W, Van Assche G, Befrits R, et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis. 2012;6:248-258.
4. Gavalas E, Kountouras J, Stergiopoulos C, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 2007;54:1074-1079.
5. Barreiro-de Acosta M, Lorenzo A, Mera J, et al. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis. 2009;3:271-276.
6. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8:231-233.
7. Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072.
8. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
9. Dignass A, Eliakim R, Magro F, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1 definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
11. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128.
12. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219-225.
13. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is Superior to monotherapy with either Agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.
14. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl JMed. 2010;362:1383-1395.
15. D'Haens G, Baert F, Van Assche G, et al; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
16. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
17. Miheller P, Kiss LS, Juhasz M, et al. Recommendations for identifying Crohn's disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75.
18. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617-2625.
19. Carbonnel F, Lavergne A, Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39:1550-1557.
20. Carbonnel F, Gargouri D, Lémann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273-279.
21. Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004;36:21-28.
22. Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637-642.
23. Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on longterm outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37:998-1004.